Browse the evidence

Higher baseline physical activity engagement during early pregnancy predicts continued moderate physical activity in the third trimester, regardless of BMI or military status.

If you are physically active before and during early pregnancy, you are highly likely to maintain that activity level through the third trimester. Focus on establishing a consistent activity routine early on, as this habit is the strongest predictor of staying active later in pregnancy, more so than your weight or job status.

Indexing peak oxygen consumption (VO2peak) to total body mass systematically underestimates cardiorespiratory fitness (CRF) in women, older adults, and individuals with obesity, whereas a novel scaling metric called Exercise Body Mass (EBM) mitigates this bias.

If you are a woman, over 40, or have obesity, your standard fitness test result (VO2peak divided by your total weight) likely makes you look less fit than you actually are. To get a fair comparison of your cardiorespiratory fitness against others or your past self, use a scaling method that accounts for your height, age, and sex (like the Exercise Body Mass metric) rather than just dividing by your total body weight.

Adherence to the American Heart Association's Life's Essential 8 (LE8) score is inversely associated with the risk of developing new-onset abdominal aortic aneurysm (AAA).

To lower your risk of abdominal aortic aneurysm, focus on optimizing your overall cardiovascular health using the Life's Essential 8 framework. This means aiming for ideal levels in blood pressure, cholesterol, blood sugar, and BMI, while never smoking, staying physically active, eating a healthy diet, and getting 7-9 hours of sleep. You don't need to be perfect; even small, consistent improvements in these areas can significantly reduce your risk over time. Prioritize quitting smoking and increasing physical activity, as these had the strongest individual effects in the study.

Orlistat (60mg OTC or 120mg Rx) is a pharmacological option that reduces fat absorption but has significant gastrointestinal side effects (steatorrhea) that can be managed through patient education.

Orlistat (60mg OTC, 120mg Rx) inhibits fat absorption. It is less effective than GLP-1s. Key to adherence is educating patients to eat a low-fat diet to avoid steatorrhea. It is an adjunct to lifestyle changes.

Targeted pharmacotherapy for obesity should focus on the MC4R pathway (e.g., MC4R agonists) for patients with specific genetic defects in upstream genes like POMC, PCSK1, or LEPR.

If you have a known genetic defect affecting your hunger hormones (like POMC or MC4R deficiencies), standard diets may fail. You should ask your doctor about genetic testing. If positive, you may be eligible for targeted medications like setmelanotide (Imcivree) that specifically fix the broken pathway.

In men under 50 without baseline hypertension or hyperglycemia, longitudinal increases in abdominal circumference and systolic blood pressure significantly increase the risk of major adverse cardiac and cerebrovascular events (MACCE).

If you are a man under 50, monitor your waist size and blood pressure regularly. Even small increases in waist circumference (e.g., 1 cm) and blood pressure over time are linked to a higher risk of heart attacks and strokes, regardless of your current weight. Preventing these increases through lifestyle management is critical for long-term heart health.

A 4 cm increase in abdominal circumference in men under 50 is associated with a 1.48 hazard ratio for developing MACCE, independent of systolic blood pressure changes.

For men under 50, gaining 4 cm around the waist over a few years nearly doubles the relative risk of a major cardiac or cerebrovascular event. Maintaining waist circumference is a key preventive strategy.

Reducing meat consumption, particularly ruminant meat, is necessary to lower greenhouse gas emissions and blue water use while simultaneously reducing the risk of cardiovascular disease, type 2 diabetes, and certain cancers.

To improve your health and reduce your environmental footprint, focus on reducing red and processed meat intake. Replace some meat meals with plant-based options like legumes, nuts, and whole grains. This shift lowers the risk of chronic diseases and reduces your diet's environmental impact.

Ultra-processed foods (UPF) contribute to negative health outcomes (obesity, diabetes, CVD, mortality) and environmental impacts, yet are often perceived as healthy due to marketing.

Limit ultra-processed foods, even if they are plant-based. Focus on whole, minimally processed foods for better health and environmental outcomes.

Discontinuation of GLP-1 agonist pharmacotherapy (e.g., semaglutide) leads to rapid weight regain, necessitating indefinite long-term treatment for maintenance.

If you use GLP-1 medications like semaglutide for weight loss, understand that stopping them will likely cause you to regain the weight quickly. These drugs treat obesity as a chronic condition, meaning you likely need to stay on them long-term to keep the weight off, regardless of cost or insurance hurdles.

Obesity (BMI ≥ 25 kg/m²) is a critical, modifiable independent risk factor that drives the bidirectional overlap between asthma and obstructive sleep apnea (OSA) through mechanisms including altered lung mechanics, airway hyperresponsiveness, and adipokine production.

If you have asthma or sleep apnea and carry excess weight, weight management is likely the most impactful single intervention you can make. Losing even a small percentage of body weight can significantly reduce the severity of sleep apnea events and improve asthma control. Focus on sustainable weight loss strategies as a primary treatment adjunct.

Patients who transfer hospitals for secondary MBS are significantly younger, have fewer obesity-related comorbidities (hypertension, GERD), and are more likely to undergo secondary surgery for recurrent weight gain compared to those who stay.

If you are younger and generally healthy but are experiencing weight regain after your first bariatric surgery, you are part of a common group that seeks a second opinion or a different surgeon for revisional surgery. This is often driven by dissatisfaction with the amount of weight lost rather than medical complications.

Newer GLP-1 and dual-agonist obesity medications produce significant weight loss (15-21%) and metabolic benefits, but discontinuation leads to weight regain.

Use GLP-1 medications as a long-term tool for weight management, not a short-term fix. Be prepared to continue treatment to maintain weight loss, as stopping often leads to regain.

Metabolic bariatric surgery is the most effective therapy for severe obesity, providing greater weight loss and mortality reduction than pharmacotherapy.

For severe obesity, surgery offers the highest chance of significant, sustained weight loss and resolution of comorbidities. Discuss eligibility with a bariatric specialist.

GLP-1 analogs (e.g., Semaglutide, Liraglutide) and dual agonists (Tirzepatide) produce significant weight loss (up to 21%) but are associated with high costs, lifelong administration requirements, and gastrointestinal side effects that may drive patients toward complementary therapies.

GLP-1 drugs (Semaglutide, Tirzepatide) are highly effective for weight loss (15-21%), but they are expensive, require lifelong injections, and cause GI side effects. If you experience side effects or cannot afford long-term use, you are not alone; many patients seek complementary therapies like TCM to manage weight and side effects.

In patients with advanced chronic liver disease (ACLD), achieving >10% body weight loss through therapeutic lifestyle interventions significantly reduces portal hypertension and improves survival, although this magnitude of weight loss is difficult to sustain long-term.

For ACLD patients, aiming for >10% weight loss via diet and exercise can significantly lower portal pressure and improve survival. However, this is hard to maintain; consider medical weight loss aids if lifestyle changes alone fail to sustain the loss.

Bariatric surgery is an effective and durable weight-loss intervention that reduces major adverse liver outcomes (MALO) and cardiovascular events in patients with MASH, though data in advanced cirrhosis is limited.

Bariatric surgery offers significant long-term benefits for liver and heart health in MASH patients. It should be considered for eligible patients, especially when other treatments fail, despite limited data in advanced cirrhosis.

New generation obesity medications (GLP-1/GIP agonists) achieve mean weight loss of 15–25% over 68–72 weeks, narrowing the efficacy gap between medical and surgical management of obesity.

New GLP-1/GIP medications like semaglutide (2.4mg weekly) and tirzepatide are highly effective, producing 15-25% weight loss over ~1.5 years. This efficacy is now comparable to surgery, making medication a primary, not just secondary, option for obesity treatment.

Poor glycemic control exacerbates dyslipidemia in diabetes by increasing hepatic VLDL production and decreasing HDL levels, while improvements in glycemic control can reverse these lipid abnormalities.

For people with diabetes, keeping blood sugar levels in range is important, but it is not enough to protect your heart. Even if your A1C is good, you likely still have abnormal cholesterol levels, specifically high triglycerides and low HDL. This is because diabetes changes how your liver processes fats. You need to monitor your lipid profile separately and likely take medication (like statins) to manage cardiovascular risk, regardless of how well your blood sugar is controlled.

Increasing cardiorespiratory fitness (CRF) reduces morbidity and mortality regardless of changes in body weight or BMI, whereas intentional weight loss in healthy overweight/obese individuals does not improve and may increase mortality risk.

Stop focusing on weight loss as the primary health goal. Instead, aim for 150 minutes of moderate-intensity physical activity per week (like brisk walking or cycling). This level of activity significantly reduces your risk of death and heart disease, regardless of whether you lose weight. Prioritize feeling stronger and more energetic over the number on the scale.

A Body Shape Index (ABSI) is associated with incident cardiovascular disease, with the highest risk observed in individuals with high ABSI combined with high RCII.

For adults over 45, monitoring your Body Shape Index (ABSI) alongside your cholesterol and inflammation levels (RCII) provides a more accurate assessment of heart disease risk than weight alone. If you have a high ABSI and high RCII, you are in a high-risk subgroup that may benefit from intensified lifestyle interventions.

Obesity and overweight status are strongly associated with higher odds of dyslipidemia in Iranian adults, with obese individuals having 2.8 times higher risk compared to normal-weight adults.

Maintaining a healthy weight is crucial for managing blood lipids. In this population, obesity significantly increases the risk of dyslipidemia. Focus on sustainable lifestyle changes including balanced nutrition and regular physical activity to manage weight and improve lipid profiles.

Physical inactivity is associated with increased odds of dyslipidemia, with inappropriate physical activity increasing the odds by 1.2 times compared to appropriate activity.

Regular physical activity helps manage blood lipids. This study found that those with inappropriate physical activity had higher odds of dyslipidemia. Aim for regular moderate-to-vigorous physical activity as part of a healthy lifestyle.

Ultra rapid lispro (URLi) administered as a bolus with basal insulin improves postprandial glucose excursions (PPGE) after breakfast more effectively than standard insulin lispro in adults with type 2 diabetes, while maintaining non-inferior HbA1c reduction and similar safety profiles regarding hypoglycemia and weight gain.

If you have Type 2 Diabetes and struggle with high blood sugar after meals, especially breakfast, ask your doctor about Ultra Rapid Lispro (URLi). It is taken exactly like your current rapid-acting insulin (just before eating) but absorbs faster to better match your food. This can significantly reduce the sharp blood sugar spikes after breakfast without increasing your risk of low blood sugar or weight gain compared to standard insulin lispro.